Tdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
Santé et médecineOne-Off2mois
FutuurVérifier la disponibilitéDonnées de résolution vérifiéesProbabilité implicite actuelle
Non 93%
Non 93%Qualité du marché
31 / 100
Faible qualitéVolume 24h
—
Liquidité
248,3 €
Faible liquiditéTraders
10
Commentaires
0
Données du marché
Mis à jour il y a 2 minutes
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
How many clinical trials will have started in Prospera by Dec 31, 2026?
FutuurWill tabernanthalog (TBG) undergo Stage II clinical trials by EOY 2026?
Manifold MarketsWill a drug that didn't go through human clinical trials be approved by 2034?
Manifold MarketsWill it be possible to obtain FDA approval for a drug based on protein folding stimulations without human clinical trials by 2035?
Manifold MarketsWill human tooth regrowth clinical trials succeed?
Manifold MarketsHantavirus pandemic in 2026?
PolymarketRègles
Researchers Jochen Buck and Lonny Levin of Weill Cornell Medicine have discovered a fast-acting and temporary male contraceptive called tdi-11861.
- This substance, a soluble adenylyl cyclase (sac) inhibitor, works by stopping sperm from swimming, rendering the subject temporarily infertile.
- According to initial studies in mice, it takes effect within half an hour, and fertility returns within a day.
- However, despite the encouraging results in mice, more animal tests and human trials are required before it can be confirmed as a breakthrough in male contraception.
- This prediction market aims to determine whether tdi-11861 will be approved for human clinical trials before or on December 31, 2026.
- The outcome will be determined based on an official announcement from the relevant regulatory bodies or agencies, such as the FDA, or news reports from major news outlets that Futuur deems credible.
